Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services

Fineline Cube Jan 23, 2026
Company Deals

PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline

Fineline Cube Jan 23, 2026
Company Deals

Bio‑Sincerity Pharma‑Tech Secures Greater China Priority Rights for Delim’s Semaglutide and Tirzepatide Portfolio

Fineline Cube Jan 23, 2026
Company Deals

TaiGen and Joincare Partner on TG‑4318 DPP1 Inhibitor for Bronchiectasis in Greater China

Fineline Cube Jan 23, 2026
Company Deals

China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy

Fineline Cube Jan 22, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials

Fineline Cube Jan 23, 2026
Company Drug

AbbVie Secures Second China Approval for Risankizumab in Ulcerative Colitis

Fineline Cube Jan 23, 2026
Company Medical Device

Ultrasound Biotechnology Earns FDA Nod for Disposable Endoscopic Ultrasound Probes

Fineline Cube Jan 19, 2024

Ultrasound Biotechnology, the Shanghai-based wholly owned subsidiary of US firm Ultrasound Wondering, Inc., has announced...

Company Deals Digital

Meinian Onehealth Collaborates with Huawei Cloud and Runda Medical on AI Health Robot

Fineline Cube Jan 19, 2024

Meinian Onehealth Healthcare (Group) Co., Ltd (SHE: 002044) has entered into a strategic partnership with...

Company Deals

Sinovac Biotech Ltd Dismisses UK Private Equity’s Nominal Share Acquisition Offer

Fineline Cube Jan 19, 2024

Sinovac Biotech Ltd (NASDAQ: SVA) has released a statement declaring that its board of directors...

Company Drug

Beijing Aosaikang Initiates Phase III Trial for Advanced Gastric Cancer Treatment

Fineline Cube Jan 18, 2024

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755), a Chinese pharmaceutical company, has registered a Phase...

Company Deals R&D

Zhejiang Dian Diagnostics Partners with Gulf Medical University for Middle East Expansion

Fineline Cube Jan 18, 2024

Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a Chinese diagnostics company, has entered into a...

Company Drug

FDA Approves Casgevy, the First CRISPR-Based Gene Editing Therapy for β-Thalassemia

Fineline Cube Jan 18, 2024

Casgevy (exagamglogene autotemcel), the pioneering gene editing therapy based on CRISPR technology, has received approval...

R&D

Sun Yat-sen University Researchers Develop AI Model for Early Ovarian Cancer Detection

Fineline Cube Jan 18, 2024

Researchers at Guangzhou’s Sun Yat-sen University Cancer Center have made a significant breakthrough with the...

Company Drug

Shanghai-Based NK CellTech Earns FDA IND Clearance for Non-Genetically Modified NK Cell Therapy

Fineline Cube Jan 18, 2024

NK CellTech, a Shanghai-based developer of NK cell therapies, has announced that it has received...

Policy / Regulatory

Hainan Province Unveils Measures to Support Innovative Drugs and Medical Devices Development

Fineline Cube Jan 18, 2024

Hainan provincial bureaus, including the Healthcare Security Administration (HSA), Healthcare Commission, and Medical Products Administration,...

Legal / IP Policy / Regulatory

Shanghai Medical Products Administration Issues Trial Measures for Pharmaceutical Quality and Safety Personnel

Fineline Cube Jan 18, 2024

The Shanghai medical products administration has released the “Measures for the Management of Key Quality...

Company Legal / IP

USPTO Invalidates Key Seagen-Held Patent in ADC Conjugation Dispute with Daiichi Sankyo

Fineline Cube Jan 18, 2024

In a surprising turn of events in the ongoing intellectual property dispute, the US Patent...

Company

Bayer Unveils New Operating Model to Drive Profitable Growth Amid Challenges

Fineline Cube Jan 18, 2024

Facing a challenging business landscape, Germany’s Bayer (ETR: BAYN) has announced a new operating model...

Company Drug

Eisai and Medivir’s Combo Therapy Advances in Liver Cancer with Positive Trial Results

Fineline Cube Jan 18, 2024

Japanese pharmaceutical company Eisai’s (TYO: 4523) kinase inhibitor Lenvima (Lenvatinib), combined with Swedish partner Medivir’s...

Legal / IP Policy / Regulatory

Shanghai Enhances Biomedicine IP Protection with New Procurement-Linked Measures

Fineline Cube Jan 18, 2024

The Shanghai Intellectual Property Administration (SIPA) has issued a notification highlighting the city’s intensified efforts...

Company Drug

Hansoh Pharmaceutical Advances Schizophrenia Treatment with HS-10509 Clinical Trial Approval

Fineline Cube Jan 18, 2024

Hansoh Pharmaceutical (HKG: 3692) has announced that it has received approval to commence clinical trials...

Company Drug

Sino Biopharmaceutical Receives NMPA Approval for Generic Revolade Equivalent

Fineline Cube Jan 18, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a major player in the Chinese pharmaceutical industry, announced that...

Company Drug

Luye Pharma’s Biosimilar Bevacizumab Gets GMP Certification in Brazil

Fineline Cube Jan 18, 2024

Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced that...

Company Drug

Regenxbio’s One-Time Gene Therapy for Wet AMD Shows Promise in Phase II Study

Fineline Cube Jan 17, 2024

Gene therapy specialist Regenxbio (NASDAQ: RGNX) has announced preliminary results from a Phase II study...

Company Drug

Takeda’s Hyqvia Approved by FDA for Chronic Inflammatory Demyelinating Polyneuropathy

Fineline Cube Jan 17, 2024

Japanese pharmaceutical company Takeda (TYO: 4502) has received an indication extension approval from the US...

Policy / Regulatory

China Regulators Chart Steady Path for ‘Huiminbao’ Medical Insurance Schemes

Fineline Cube Jan 17, 2024

The China Banking and Insurance Regulatory Commission (CBIRC) and National Healthcare Security Administration (NHSA) have...

Posts pagination

1 … 360 361 362 … 613

Recent updates

  • Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services
  • Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials
  • PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline
  • J&J Reports $94.2 Billion Full‑Year 2025 Revenue, Driven by Oncology and Immunology Growth
  • AbbVie Secures Second China Approval for Risankizumab in Ulcerative Colitis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services

Company Drug

Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials

Company Deals

PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline

Company

J&J Reports $94.2 Billion Full‑Year 2025 Revenue, Driven by Oncology and Immunology Growth

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.